多西紫杉醇单药化疗在老年中晚期非小细胞肺癌的近期疗效分析  

Clinical observation of docetaxel in treating elder advanced non-small cell lung cancer

作　　者：胡晓璐[1,2] 杨毅[1,2] 李高峰[1,2] 

机构地区：[1]云南省肿瘤医院 [2]昆明医学院第三附属医院,650118

出　　处：《中国医学创新》2011年第6期32-33,共2页Medical Innovation of China

基　　金：云南省科技厅社会发展科技计划应用基础研究项目(项目批准号:2009ZC120M);云南省教育厅资助项目(项目批准号:09y0173)

摘　　要：目的观察了解多西紫杉醇单药化疗在老年晚期非小^(NSCLC)的临床疗效和毒性反应。方法 29例Ⅲ~Ⅳ期NSCLC老年患者均经病理组织学和(或)细胞学检查确诊。多西紫杉醇单药治疗后评价疗效。结果 29例患者均可评价,获得CR2例,PR10例,有效率41.4%(12/29)。1年生存率为48.3%(14/29)。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论多西紫杉醇单药化疗治疗老年晚期NSCLC有较好疗效,可明显改善患者生存质量,毒副反应轻,易于耐受。Objective To evaluate the clinical effect and toxieity of docetaxel in treating elder advanced non - small cell lung cancer（NSCLC）. Methods 29 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received and were evaluated effect after 2 - 4 cycles. Results Complete remisson （CR） was observrd in 2 cases and PR in 10 cases, the total response rate was 41.4% （12/29）. 1 - year survival rate was 48. 3% （14/29）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. Conclusion The regimen of pemetrexed plus cisplation is effective, safe and well - tolerable in the treatment of eider advanced NSCLC. It significantly prolong the patients, survival time.

关 键 词：非小细胞肺癌 多西紫杉醇 老年患者 

分 类 号：R734.2[医药卫生—肿瘤]